17:01:45 RRSAgent has joined #hcls2 17:01:45 logging to http://www.w3.org/2011/11/17-hcls2-irc 17:01:51 rrsagent, make logs public 17:01:59 matthias_samwald has joined #hcls2 17:02:11 Chair: michel 17:02:17 ScribeNick: bobP 17:02:27 zakim, this is tmo 17:02:27 ok, michel; that matches SW_HCLS(TMO)11:00AM 17:02:35 zakim, who is here? 17:02:37 On the phone I see Scott_Bauer, Joseph_Scheuhammer, Bob_Powers, Joanne_Luciano, [IPcaller] 17:02:38 On IRC I see matthias_samwald, RRSAgent, Zakim, adrien, michel, bobP, Mary, RickKiefer, ericP 17:02:38 Joanne has joined #hcls2 17:03:28 BobF has joined #hcls2 17:03:45 +Scott_Bauer.a 17:04:13 + +62427aaaa 17:04:21 mscottm2 has joined #hcls2 17:05:10 +[IPcaller.a] 17:05:27 can't hear you - Michel? 17:05:37 -[IPcaller.a] 17:05:41 severely breaking up 17:05:51 this was noisy AND breaking up. 17:08:27 scribenick bobP 17:08:53 +??P27 17:09:00 Matthias: Michel and I extended TMO, targeted to represent... 17:09:29 RickKiefer has joined #hcls2 17:09:34 (Michel is talking from an advanced com center) 17:09:58 LOL 17:10:11 michel has joined #hcls2 17:10:21 Matthias: after a lot of consideration, edited classes for genetic variantion 17:10:42 ... also edited other classes of a general nature 17:10:58 ... look at TMO as it is on BioPortal 17:11:15 ... namespace of TMO is identical to that used to enhance 17:11:26 http://bioportal.bioontology.org/ontologies/1461 17:11:37 ... so all of changes went live to BioPortal :) 17:12:08 ... maybe we should reconsider the authoritative source 17:12:36 Michel: +1 to controlled releases 17:12:43 iker has joined #hcls2 17:13:10 Matthias: It is going to a release file 17:13:41 ... latest on BioPortal 1.02 17:13:57 http://bioportal.bioontology.org/ontologies/46121?p=terms 17:14:14 bobP sees it 17:14:37 +[IPcaller.a] 17:15:06 Joanne sees it 17:16:03 Matthias: Tried to follow the realist approach; variation is not an abstract entity like sequence 17:16:21 JoanneLuciano has joined #hcls2 17:16:43 ... this approach tried to build on established principles; represent as material entity 17:17:15 Joanne: Working from authoritative source? 17:17:41 Matthias: Mixture. Looked at DBs and how they representetd variation 17:18:04 ... dbSNP also has short indels(?) etc 17:18:24 ... still quite open. Is this approach good? 17:18:40 ... also, how to represent more detail? 17:19:03 +EricP 17:19:28 ... Ex class region w SNP. Originally from Michel, represent right down to nucleotide level 17:20:12 ... SNP would be a subclass of nucleotide (?) 17:20:18 +??P0 17:20:28 Lena has joined #hcls2 17:20:42 ... concerned that this might not be practical. Gets complex beyond simple SNP 17:21:07 ... propose to identify SNP thru datatype property, as a sequence stream 17:21:27 ... go w. the more normal way that SNPs are represented in real DBs 17:21:46 "as strings of characters" 17:22:14 BobF: Q Current models for variants. SNPs need a reference sequence 17:22:28 ... how does that fit here? 17:22:54 Matthias: Refer to loci w/in genome where loci have relation to reference genomes 17:23:33 ... found in relation to reference. Would suggest we find ont rep that is independent of standard geneome 17:23:47 ... in context of surrounding DNA 17:24:05 https://docs.google.com/document/d/1BeaU3VJW1S_R3eB5ncrcW9wJ-lMU4xdmxCdjH8E0i5s/edit?hl=en_US 17:24:11 ... but may be useful to keep relation to reference genome 17:24:39 Michel: We did consider where this residue is a SNP, partOf some reference genome 17:24:53 ... that's a way to make the connection 17:25:04 The NCI Life Sciences DAM may be a useful reference: http://ncientarch.info/sandbox/LSDAM2_2_1/ 17:26:27 Matthias: SNP would go out the material branch; reference would go out the information entity branch 17:26:57 Michel: Need to make connection( didn't quite get this) 17:28:30 mscottm2 has joined #hcls2 17:28:42 BobF: Been working w NCI on modeling molecular entities, 17:28:54 ... in this model we do address these issues 17:29:10 ericP: Guide us? 17:29:20 http://ncientarch.info/sandbox/LSDAM2_2_1/ 17:29:20 http://ncientarch.info/sandbox/LSDAM2_2_1/ 17:29:39 http://ncientarch.info/sandbox/LSDAM2_2_1/ 17:30:10 @matthias_samwald: if found "reference genomic sequence"@en in the tmo, it this what you meant? 17:30:52 http://ncientarch.info/sandbox/LSDAM2_2_1/ 17:31:13 (my image is very narrow!) 17:33:00 Joanne: This works for me +1 17:33:24 Scott: TMO has DNA-region-w-SNP 17:33:31 would that look like this in turtle ? [ a NucleicAcidSequenceFeature ] NucleicAcidPhysicalLocation [ a NucleicAcidSequence ] . 17:33:40 ... would mke SNP a property of a region 17:34:20 Joanne: SNP needs more than one nucleotide reference 17:34:20 or in RDFS: { :NucleicAcidPhysicalLocation rdfs:domain :NucleicAcidSequenceFeature ; rdfs:range :NucleicAcidSequence . } 17:34:44 Matthias: Want to create this ont from scratch on top of TMO? 17:35:06 ... analyzed SO a lot; claims to have everything figured out. 17:35:16 ... but hard to understand 17:35:51 Joanne: Q (didn't get) 17:36:23 Matthias: SNP needs a population. Use the knowledge to give special meaning to regions of the genome 17:37:41 ... liturature tries to avoid mutation (answer to Helen's Q) 17:37:58 Michel: Seq, feature, what are you trying to say? 17:38:21 ... actually we have a different molecular material? 17:38:40 ... is it really a feature of a sequence? 17:39:18 Matthias: Everything based on individual, w specific regions etc. Then create universals 17:39:31 ... to group individuals 17:40:18 BobF: Two different levels of granularity here 17:40:57 ... ultimately we are talking about a physically different DNA, should be treating like a physical entity 17:41:24 ... from patient's perspective, show me what proceeds from this reality(?) 17:41:47 ... different from looking at populations, different perspectives 17:42:07 ericP: Does one of these align more closely? Are use cases similar? 17:42:31 BobP: Both perspectives, but could not drill into this area as much as would have liked 17:42:46 ... LSDAM, will be taking these considerations back 17:43:04 -[IPcaller.a] 17:43:21 ... tried to come up w high level use cases, so successful for these 17:43:41 ... but instantated in different ways for different use cases 17:44:08 Michel: TMO distinguishes between physical and sequences 17:44:33 ... we do have both concepts, both are useful. 17:44:44 ... what are individuals composed of? 17:45:07 ... we do geno- and phenotyping both 17:45:40 BobF: LSDAM is looking at a translation to OWL 17:45:52 ericP: Opportunity here 17:46:10 Matthias: Could apply a Xform to RDF 17:46:48 ... TMO trying to do in this more complicated way, w ont principles 17:47:20 ... advantages for reasoning, etc; disadvantage makes things complicated 17:47:37 ... putting this realist view on top 17:48:09 BobF: LSDAM used UML b/c of the existing infrastructure 17:48:26 ... would welcome the input from OWL experts here 17:48:50 Scott: Taking ont approach so we can use reasoning as well as easy integration 17:49:15 ... choice should be tested against a reasoning task 17:49:33 ... want a concrete set of test cases, to reason over patient data etc 17:49:43 ... would help us ground the conversation 17:50:19 Matthias: Should try to carry this on, try a prototye 17:50:29 ... OWL reasoning to classify patients 17:51:07 ... practically, different models give confusion on variation in individuals vs in populations 17:51:22 Lena: Patient instance of population? 17:51:49 Matthias: No. A population is a specific entity. 17:52:26 Lena: Patient part of a cohort, so patient could be an instance of cohort class. 17:52:41 BobF: Cohort could be a kind of cohort 17:52:55 (!) kind of popultion 17:53:22 Michel: TMO, would want to assign attributes to populations 17:53:59 ... can have cohorts of studies, etc. Averages over individuals, as opposed to specific characteristic 17:54:19 Matthias: Should agree on community process to address this. 17:56:18 Scott: We started w use cases for sparql queries 17:56:29 ... Michel put up axioms for ethnicity 17:57:03 ... clinical decision support, might not make a difference for which way to go. 17:58:06 Michel: DrugBank geno-pheno all in OWL. Can gain from clear formalization 17:58:30 ... mixing categories then we can't leverage from what we have 17:58:45 ... want to go beyond just linked data. 17:59:12 ericP: If we write down in LD vs If we write down formally 17:59:47 Lena: Linked data will have new stuff, should be able to express in TMO 18:00:02 Scott: ...different demands 18:00:44 Matthias: TMO approach now is ontological; vs put up raw RDF 18:01:38 -Joanne_Luciano 18:01:40 ... suggest end of Jan 2012 18:02:32 Scott: Pgx paper, there are prods from reviewers 18:03:04 ... want more material. Want what we're working on now! 18:03:21 ... PGx for Future Medicine 18:04:39 Lena has bragging rights. We await! 18:05:38 try to document all SPARQL endpoints and datasets you create on http://www.w3.org/wiki/HCLSIG/pharmacogenomics_2012 !! 18:07:06 Mary has left #hcls2 18:07:17 -Joseph_Scheuhammer 18:09:21 -[IPcaller] 18:09:27 rrsagent, draft minutes 18:09:27 I have made the request to generate http://www.w3.org/2011/11/17-hcls2-minutes.html michel 18:09:34 -??P27 18:09:41 rrsagent, make log world-visible 18:11:34 -Scott_Bauer.a 18:19:17 -Bob_Powers 18:22:44 -??P0 18:22:46 -EricP 18:22:48 - +62427aaaa 18:22:56 -Scott_Bauer 18:22:58 SW_HCLS(TMO)11:00AM has ended 18:23:00 Attendees were Scott_Bauer, Joseph_Scheuhammer, Bob_Powers, Joanne_Luciano, [IPcaller], +62427aaaa, EricP 18:23:03 mscottm2 has joined #hcls2 19:26:13 Zakim has left #hcls2 20:30:07 matthias_samwald has joined #hcls2